Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave

Coalition, Dutch Covid Thrombosis; Kaptein, Fleur H.J.; Stals, Milou A.M.; Grootenboers, Mjjh; Braken, Sje; Burggraaf, Louise; Bussel, Bas C.T. van; Cannegieter, Suzanne C.; Cate, Hugo Ten; Endeman, Henrik; Gommers, Diederik; Guldener, Coen van; Jonge, Evert de; Juffermans, Nicole P.; Kant, K Merijn; Kevenaar, M E; Koster, Stephanie C E; Kroft, Lucia J.M.; Kruip, Marieke J.H.A.; Leentjens, Jenneke; Maréchal, Cédric Le; Soei, Y L; Tjepkema, L; Visser, Chantal; Klok, Frederikus A.; Huisman, Menno V.

doi:10.1016/j.thromres.2020.12.019

Cited by 97 publications

(89 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to a recent systematic review of 28 studies totaling 2928 ICU COVID-19 patients, thrombotic complications occurred in 34% of patients, including 12.6% with pulmonary embolism (PE) [63]. In a recent Dutch survey of 947 patients, including 358 ICU patients, the cumulative incidence of venous thromboembolic complications after 30 days amounted to 19% in non-ICU and 23% in ICU patients [64]. Although the risk of PE is also increased in patients with pneumonia and ARDS unrelated to COVID, a significantly higher proportion of COVID-19 patients develop this complication, as notably reported by Helms et al [65].…”

Section: Increase Of the Pulmonary Hydraulic Load Pulmonary Vascular Obstructionmentioning

confidence: 99%

“…In addition to this high incidence, COVID-19 associated PE frequently develops in spite of anticoagulant thrombo-prophylaxis [64,67], is characterized by a lower thrombus load and a more peripheral distribution than non-COVID PE [67,68], and combines both pulmonary arterial and venous thrombotic manifestations [69]. Furthermore, pathological examination of autopsy specimen of COVID-19 ARDS patients revealed the presence of microthrombotic obstruction of small pulmonary vessels, which were nine times more prevalent than in other forms of ARDS [70,71], and which displayed features of plateletrich thrombotic microangiopathy [72].…”

Section: Increase Of the Pulmonary Hydraulic Load Pulmonary Vascular Obstructionmentioning

confidence: 99%

See 1 more Smart Citation

The Right Ventricle in COVID-19

Bonnemain

Ltaief

Liaudet

2021

JCM

View full text Add to dashboard Cite

Infection with the novel severe acute respiratory coronavirus-2 (SARS-CoV2) results in COVID-19, a disease primarily affecting the respiratory system to provoke a spectrum of clinical manifestations, the most severe being acute respiratory distress syndrome (ARDS). A significant proportion of COVID-19 patients also develop various cardiac complications, among which dysfunction of the right ventricle (RV) appears particularly common, especially in severe forms of the disease, and which is associated with a dismal prognosis. Echocardiographic studies indeed reveal right ventricular dysfunction in up to 40% of patients, a proportion even greater when the RV is explored with strain imaging echocardiography. The pathophysiological mechanisms of RV dysfunction in COVID-19 include processes increasing the pulmonary vascular hydraulic load and others reducing RV contractility, which precipitate the acute uncoupling of the RV with the pulmonary circulation. Understanding these mechanisms provides the fundamental basis for the adequate therapeutic management of RV dysfunction, which incorporates protective mechanical ventilation, the prevention and treatment of pulmonary vasoconstriction and thrombotic complications, as well as the appropriate management of RV preload and contractility. This comprehensive review provides a detailed update of the evidence of RV dysfunction in COVID-19, its pathophysiological mechanisms, and its therapy.

show abstract

Section: Increase Of the Pulmonary Hydraulic Load Pulmonary Vascular Obstructionmentioning

confidence: 99%

Section: Increase Of the Pulmonary Hydraulic Load Pulmonary Vascular Obstructionmentioning

confidence: 99%

The Right Ventricle in COVID-19

Bonnemain

Ltaief

Liaudet

2021

JCM

View full text Add to dashboard Cite

show abstract

“… Immunomodulatory therapies (corticosteroids, interleukin-6 receptor antagonists) are now widely used, but their effect on the thrombotic risk is unknown. Despite improved survival, thrombotic complications remain a concern [2] . …”

Section: Introductionmentioning

confidence: 99%

Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021)

Garrigue

Albaladéjo

Blais

et al. 2021

Anaesthesia Critical Care & Pain Medicine

View full text Add to dashboard Cite

“…A significant number will present in the setting of critical illness. One study showed that 13% of 358 patients in the intensive care unit were found to have a thrombotic event, including but not limited to pulmonary embolism, deep vein thrombosis, and ALI [27] . However, in another study, 38.1% of thrombotic events were seen in patients with mild COVID-19 [25] .…”

Section: Presentationmentioning

confidence: 99%

A review of acute limb ischemia in COVID-positive patients

Ilonzo

Judelson

Al-Jundi

et al. 2021

Seminars in Vascular Surgery

View full text Add to dashboard Cite

This literature review discusses the current evidence on acute limb ischemia (ALI) in patients with COVID-19. Throughout the pandemic, these patients have been at increased risk of arterial thrombotic events and subsequent mortality as a result of a hypercoagulable state. The exact mechanism of thrombosis is unknown; however arterial thrombosis may be due to invasion of endothelial cells via angiotensin-converting enzyme 2 (ACE2) receptors, endothelial injury from inflammation, or even free-floating aortic thrombus. Multiple studies have been performed evaluating the medical and surgical management of these patients; the decision to proceed with operative intervention is dependent on the patient’s clinical status as it relates to COVID-19 and morbidity of that disease. The interventions afforded typically include anticoagulation in patients undergoing palliation; alternatively, thrombectomy (endovascular and open) is utilized in other patients. There is a high risk of rethrombosis, despite anticoagulation, given persistent endothelial injury from the virus. Postoperative mortality can be high in these patients.

show abstract

Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave

Cited by 97 publications

References 32 publications

The Right Ventricle in COVID-19

The Right Ventricle in COVID-19

Prevention of venous thromboembolism and haemostasis monitoring in patients with COVID-19: Updated proposals (April 2021)

A review of acute limb ischemia in COVID-positive patients

Contact Info

Product

Resources

About